Search research articles
Contact Us
Filters
Showing results (321-330 of 467) with videos related to
Page
of 47
Sort By:
Antiviral Therapy
|
October 13, 2005
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial
Ulrik B Dragsted, Jan Gerstoft, Mike Youle, et al.
Viruses
|
August 10, 2021
Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study
Rossana Scutari, Valentino Costabile, Laura Galli, et al.
International Journal of Antimicrobial Agents
|
December 1, 2020
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database
Francesca Lombardi, Andrea Giacomelli, Daniele Armenia, et al.
The Journal of Antimicrobial Chemotherapy
|
March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial
Laura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
The Journal of Antimicrobial Chemotherapy
|
December 27, 2024
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry
Tommaso Clemente, Sara Diotallevi, Davide Minisci, et al.
Journal of Clinical Medicine
|
January 21, 2022
Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy
Antonella Cingolani, Alessandro Tavelli, Franco Maggiolo, et al.
Drug Design, Development and Therapy
|
October 21, 2022
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
Vincenzo Spagnuolo, Marta Voarino, Marco Tonelli, et al.
Pharmacogenetics and Genomics
|
January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
Marco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Antiviral Therapy
|
April 28, 2006
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients
Andrea Antinori, Maria Paola Trotta, Paola Nasta, et al.
CMI Communications
|
May 6, 2026
Clinical and Genomic Characterization of Serratia Bloodstream Infections
Roberta Monardo, Lawrence P Park, Felicia Ruffin, et al.
Page
of 47
Search research articles
Search
Showing results (321-330 of 467) with videos related to
Sort By:
Page
of 47
Antiviral Therapy
|
October 13, 2005
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial
Ulrik B Dragsted, Jan Gerstoft, Mike Youle, et al.
Viruses
|
August 10, 2021
Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study
Rossana Scutari, Valentino Costabile, Laura Galli, et al.
International Journal of Antimicrobial Agents
|
December 1, 2020
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database
Francesca Lombardi, Andrea Giacomelli, Daniele Armenia, et al.
The Journal of Antimicrobial Chemotherapy
|
March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial
Laura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
The Journal of Antimicrobial Chemotherapy
|
December 27, 2024
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry
Tommaso Clemente, Sara Diotallevi, Davide Minisci, et al.
Journal of Clinical Medicine
|
January 21, 2022
Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy
Antonella Cingolani, Alessandro Tavelli, Franco Maggiolo, et al.
Drug Design, Development and Therapy
|
October 21, 2022
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
Vincenzo Spagnuolo, Marta Voarino, Marco Tonelli, et al.
Pharmacogenetics and Genomics
|
January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
Marco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Antiviral Therapy
|
April 28, 2006
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients
Andrea Antinori, Maria Paola Trotta, Paola Nasta, et al.
CMI Communications
|
May 6, 2026
Clinical and Genomic Characterization of Serratia Bloodstream Infections
Roberta Monardo, Lawrence P Park, Felicia Ruffin, et al.
Page
of 47